Dr. Tyler Donald Lash, MD

Dr. Lash practices at WK Hematology Oncology Associates in Shreveport, Louisiana.

Dr. Lash's NPI, 1437449949, was assigned on April 18, 2011. Dr. Lash graduated from LSU School of Medicine in Shreveport in 2011. Dr. Lash holds Louisiana license 304955.

Dr. Lash's primary practice is WK Hematology Oncology Associates, at 2600 Kings Hwy, Shreveport, LA 71103 in Caddo Parish. The practice phone is (318) 212-8620.

Dr. Lash's primary practice is WK Hematology Oncology Associates in Shreveport, Louisiana. Dr. Lash is also affiliated with Willis Knighton North. The medical group on file is Willis Knighton Genetics. Dmand AI also links Dr. Lash to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lash practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lash's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lash is licensed in Louisiana.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Lash treats.

CMS data shows 2,526 Medicare services from Dr. Lash across 9 procedure codes in 2024, for 601 Medicare patients. Medicare paid $205,747 for them.

CMS counts 601 Medicare patients who saw Dr. Lash in 2024. The largest group is 65 to 74, with 285 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lash's median patient age at 71, with 54% women.

In 2024, Dr. Lash wrote 2,488 Medicare Part D claims for 301 patients. 79% of them were for generic drugs. CMS names the drug for 2,215 of them, across 57 drugs with 11 or more claims each, at $5,354,455 in total drug cost. In 2023, CMS named 1,922 claims across 49 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Lash for performance year 2024, reported through an alternative payment model (APM). Dr. Lash accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 318 general payments to Dr. Lash from 43 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,144.

Dr. Lash graduated from LSU School of Medicine in Shreveport in 2011.

Dr. Lash is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.